Oxymatrine targets EGFRp-Tyr845and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 2, 2015, Pages 353-363

  Guo, Bingyu ^a   Zhang, Tingting ^a   Su, Jingyuan ^a   Wang, Kaiwen ^a   Li, Xiaoming ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

EGFR; Gastric cancer; Oxymatrine; Phosphorylation; Signaling pathway

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 9; COFILIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; LIM KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OXYMATRINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; ALKALOID; ANTINEOPLASTIC AGENT; QUINOLIZINE DERIVATIVE; TYROSINE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL LINE;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM INVASIVENESS; PHOSPHORYLATION; QUINOLIZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TYROSINE;

EID: 84925511067     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2651-1     Document Type: Article

References (31)

1. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S (2010) Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 9:121. doi:10.1186/1476-4598-9-121
2. Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng M, Zhao D, Li F (2012) LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett 317(1):24-32. doi:10.1016/j.canlet.2011.11.007
3. Wang P, An F, Zhuang X, Liu J, Zhao L, Zhang B, Liu L, Lin P, Li M (2014) Chronopharmacology and mechanism of antitumor effect of erlotinib in lewis tumor-bearing mice. PLoS One 9(7):e101720. doi:10.1371/journal.pone.0101720
4. Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D (2011) Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev 37(8):599-610. doi:10.1016/j.ctrv.2011.03.007
5. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1):110-124
6. Song G, Luo Q, Qin J, Wang L, Shi Y, Sun C (2006) Effects of oxymatrine on proliferation and apoptosis in human hepatoma cells. Colloids Surf B 48(1):1-5. doi:10.1016/j.colsurfb.2005.12.012
7. Wu XS, Yang T, Gu J, Li ML, Wu WG, Weng H, Ding Q, Mu JS, Bao RF, Shu YJ, Cao Y, Wang XA, Ding QC, Dong P, Xie SF, Liu YB (2014) Effects of oxymatrine on the apoptosis and proliferation of gallbladder cancer cells. Anticancer Drugs. doi:10.1097/CAD.0000000000000124
8. Liu J, Yao Y, Ding H, Chen R (2014) Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells. Tumour Biol 35(6):5409-5415. doi:10.1007/s13277-014-1705-7
9. Zhang Y, Liu H, Jin J, Zhu X, Lu L, Jiang H (2010) The role of endogenous reactive oxygen species in oxymatrine-induced caspase-3-dependent apoptosis in human melanoma A375 cells. Anticancer Drugs 21(5):494-501. doi:10.1097/CAD.0b013e328336e927
10. Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu W, Qi X, Zhu X, Pei Y, Lin H (2011) Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells. Med Oncol 28(Suppl 1):99-107. doi:10.1007/s12032-010-9721-y
11. Zou J, Ran ZH, Xu Q, Xiao SD (2005) Experimental study of the killing effects of oxymatrine on human colon cancer cell line SW1116. Chin J Dig Dis 6(1):15-20. doi:10.1111/j.1443-9573.2005.00181.x
12. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15(1):69-79. doi:10.1245/s10434-007-9596-0
13. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958-2970
14. Hong L, Han Y, Yang J, Zhang H, Jin Y, Brain L, Li M, Zhao Q (2013) Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis. Gene 529(1):69-72. doi:10.1016/j.gene.2013.07.106
15. Gusterson BA (1992) Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 28(1):263-267
16. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18(3):510-517. doi:10.1093/annonc/mdl459
17. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbb-2 in human gastric cancer. Cancer 75(S6):1418-1425
18. Albanell J, Rojo F, Baselga J (2001) Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 28(5 Suppl 16):56-66
19. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(18 Suppl):1S-13S
20. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A (2003) Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 1(6):438-445
21. Glineur D, Boodhwani M, Poncelet A, De Kerchove L, Etienne PY, Noirhomme P, Deceuninck P, Michel X, El Khoury G, Hanet C (2010) Comparison of fractional flow reserve of composite Y-grafts with saphenous vein or right internal thoracic arteries. J Thorac Cardiovasc Surg 140(3):639-645. doi:10.1016/j.jtcvs.2009.11.013
22. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T (2008) Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 74(1-2):76-83. doi:10.1159/000139127
23. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T (2008) Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 14(10):3022-3029. doi:10.1158/1078-0432.CCR-07-1898
24. Pal HC, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA, Afaq F (2013) Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One 8(10):e77270. doi:10.1371/journal.pone.0077270
25. Morozevich GE, Kozlova NI, Ushakova NA, Preobrazhenskaya ME, Berman AE (2012) Integrin alpha5beta1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells. Aging 4(5):368-374
26. Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ, Yu XG (2012) ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40(5):1714-1724. doi:10.3892/ijo.2011.1320
27. Baki A, Bielik A, Molnar L, Szendrei G, Keseru GM (2007) A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors. Assay Drug Dev Technol 5(1):75-83. doi:10.1089/adt.2006.029
28. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
29. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE (2008) Androgen receptor and invasion in prostate cancer. Cancer Res 68(4):1128-1135. doi:10.1158/0008-5472.CAN-07-1929
30. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C (2009) Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34(4):897-903
31. Ahmed T, Shea K, Masters JR, Jones GE, Wells CM (2008) A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal 20(7):1320-1328. doi:10.1016/j.cellsig.2008.02.021